Dynavax Initiates Phase I Trial Of Hepatitis B Therapy

Fri, 02 Mar 2007 02:00 PM EST

... Dynavax Technologies Corporation (Nasdaq: DVAX) today announced that it had initiated a Phase 1 trial of its novel therapy for chronic hepatitis B virus (HBV) infection. The trial is being conducted in Hamburg, Germany and will enroll 20 healthy subjects to evaluate the safety of the therapy at two dosing schedules. [click link for full article] ...